<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674774</url>
  </required_header>
  <id_info>
    <org_study_id>OC20MIDI0057</org_study_id>
    <nct_id>NCT04674774</nct_id>
  </id_info>
  <brief_title>Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection</brief_title>
  <official_title>Efficacy of Tegoprazan Based Bismuth Quadruple Therapy Compared With Bismuth Quadruple Therapy for Helicobacter Pylori Infection: Randomized, Double-blind, Active-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incheon St.Mary's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate eradication rate, drug compliance, and adverse events in&#xD;
      patients with confirmed Helicobacter pylori infection between tegoprazan, bismuth,&#xD;
      metronidazole, and tetracycline for 14 days (TBMT) and PPI, bismuth, metronidazole, and&#xD;
      tetracycline for 14 days (LBMT)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, double-blind, randomized, active-controlled study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 28, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rate of each group</measure>
    <time_frame>UBT test 4 weeks after completion of eradication treatment</time_frame>
    <description>H. pylori eradication rate of each group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>tegoprazan based bismuth quadruple therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tegoprazan based bismuth quadruple therapy group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPI based bismuth quadruple therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PPI based bismuth quadruple therapy group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan</intervention_name>
    <description>oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days</description>
    <arm_group_label>tegoprazan based bismuth quadruple therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day</description>
    <arm_group_label>PPI based bismuth quadruple therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        patients who male or female aged 19 to 75 years old and fall under the following conditions&#xD;
        with confirmed helicobacter pylori infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients who have H.pylori eradication history&#xD;
&#xD;
          2. patients with history of gastric cancer surgery&#xD;
&#xD;
          3. patients who have taken antibiotics within 4 weeks prior to trial&#xD;
&#xD;
          4. a person who taking HIV protease inhibitors (atazanavir, nelfinavir) or a drug&#xD;
             containing rilpivirine&#xD;
&#xD;
          5. pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joon Sung Kim, Ph.D.</last_name>
    <phone>82-32-280-5056</phone>
    <email>kijoons@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Incheon St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Joon Sung Kim, Ph.D.</last_name>
      <email>kijoons@catholic.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Joon Sung Kim</last_name>
      <email>kijoons@catholic.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Incheon St.Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Joon Sung Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

